Another COVID-19 vaccine developed by SK Bioscience has been approved for clinical trials in Korea. The MFDS announced on the 31st that it has approved the clinical trial of the domestically developed COVID-19 vaccine GBP510. GBP510 is a vaccine candidate being developed by SK Bioscience and is different from NBP2001, which was clinically approved in November.

This clinical trial is to evaluate the safety and immunogenicity of GBP510 in healthy adults, and phase II will be sequentially conducted after phase I. Immunogenicity refers to the rate of increase in neutralizing antibody that eliminates or lowers viral infectivity.

GBP510 is a recombinant vaccine made using gene recombination tec